Skip to content

Investors / Press Releases


The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.


Filter Releases
 
Press Releases
Date Title and Summary View
Nov 14, 2017
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced data analysis orally presented today at the American Heart Association (AHA) 2017 Scientific Sessions...
Nov 13, 2017
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced an oral presentation titled, "Icosapent Ethyl Reduces Potentially Atherogenic Lipid and Inflammatory ...
Nov 13, 2017
Higher Rates of Myocardial Infarction (Heart Attack) and Revascularization Procedures in Patients with High Triglycerides Were Drivers of the Composite Outcome MACE Rate 35% Higher in Patients Who, Despite Statin Therapy, Have Elevated Triglyceride Levels Cost of Health Care Nearly 15% Higher in this Higher Risk Patient Population BEDMINSTER...
Nov 7, 2017
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present a ...
Nov 1, 2017
Nov 1, 2017
Record-High Net Product Revenue of $47.1 Million in Third Quarter Management to Host Conference Call Today at 8:00 a.m. ET BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to impr...
Oct 25, 2017
BEDMINSTER, N.J., and DUBLIN, Ireland, Oct. 25, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the co...
Sep 25, 2017
BEDMINSTER, N.J., DUBLIN, Ireland, and TORONTO, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) and HLS Therapeutics Inc. ("HLS"), announced today an exclusive agreement between the parties to register, commercialize and distribute Vascepa® (icosapent ethyl) capsules in Canada. Amarin and HLS anticipate submitting an ...
Sep 20, 2017
BEDMINSTER, N.J., and DUBLIN, Ireland, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present a...
Sep 13, 2017
BEDMINSTER, N.J. and DUBLIN, Ireland, Sept. 13, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Mark W. Salyer has joined Amarin as Chief Commercial Officer. In this newly created position, Mr. Salyer will work to build on the company's recent revenue growth and lead future global commercial expansion plans and ...
Sep 6, 2017
BEDMINSTER, N.J., and DUBLIN, Ireland, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present a...
Aug 14, 2017
BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced that, as expected, the independent data monitoring committee (DMC) has completed its review of the scheduled pre-specified interim efficacy and safety analysis for the REDUCE-IT cardiovascular outcomes study and has recommended t...
Aug 2, 2017
Record-High Net Product Revenue of $44.9 Million in Second Quarter Increasing Guidance on Full Year Net Product Revenue to $165-175 Million Management to Host Conference Call at 8:00 a.m. ET Today BEDMINSTER, N.J., and DUBLIN, Ireland, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focus...
Jul 26, 2017
BEDMINSTER, N.J., and DUBLIN, Ireland, July 26, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the co...
Jun 12, 2017
BEDMINSTER, N.J. and DUBLIN, Ireland, June 12, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced two EPA-related data presentations unveiled this week at the American Diabetes Association® 77th...
Page:
...
Next Last
 
= add release to Briefcase